



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
Group Art Unit (Not yet assigned)

Patent Application of

David L. Epstein

Application No. 10/580,477

Confirmation No.: Not yet assigned

Filed: May 24, 2006

Examiner: Not yet assigned

"A METHOD OF PREVENTING OR
TREATING GLAUCOMA"

I, Nanci A. Musich, hereby certify that this correspondence is being deposited with the US Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date of my signature.


Signature

AUGUST 8, 2006
Date of Signature

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR §1.97(b)(3)


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08A and/or PTO/SB/08B and copies of non-U.S. patent references are attached. Citation of these references is respectfully requested.

No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,


Gregory J. Hartwig
Reg. No. 46,761

File No. 017425-9004-01

Michael Best & Friedrich LLP
100 East Wisconsin Avenue, Suite 3300
Milwaukee, Wisconsin 53202-4108
414.271.6560
T:\Client\017425\9004\VA1656877.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

| | |
|------------------------|------------------|
| Application Number | 10/580,477 |
| Filing Date | May 24, 2006 |
| First named Inventor | David L. EPSTEIN |
| Group Art Unit | Not yet assigned |
| Examiner name | Not yet assigned |
| Attorney Docket Number | 017425-9004-01 |

U.S. Patent Documents

| Examiner Initials | U.S. Patent Document Number | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document |
|-------------------|-----------------------------|---|---------------------------------------|
| /ZF/ | 3,983,140 | Endo et al. | 09/28/1976 |
| | 4,231,938 | Monaghan et al. | 11/04/1980 |
| | 4,346,227 | Terahara et al. | 08/24/1982 |
| | 4,444,784 | Hoffman et al. | 04/24/1984 |
| | 4,450,171 | Hoffman et al. | 05/22/1984 |
| | 4,681,893 | Roth | 07/21/1987 |
| | 4,739,073 | Kathawala | 04/19/1988 |
| | 5,041,450 | Chiou et al. | 08/20/1991 |
| | 5,134,124 | Nisato et al. | 07/28/1992 |
| | 5,177,080 | Angerbauer et al. | 01/05/1993 |
| | 5,273,995 | Roth | 12/28/1993 |
| | 5,284,953 | Ohara et al. | 02/08/1994 |
| | 5,354,772 | Kathawala | 10/11/1994 |
| | 5,356,896 | Kabadi et al. | 10/18/1994 |
| | 5,536,814 | Ruoslahti et al. | 07/16/1996 |
| | 5,629,294 | diZerega et al. | 05/13/1997 |
| | 5,683,867 | Biesecker et al. | 11/04/1997 |
| | 5,733,558 | Breton et al. | 03/31/1998 |

Examiner
Signature

/Zohreh Fay/ (08/01/2010)

Date
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | |
|---|--|-----------------------------|---|---------------------------------------|
| Substitute for form 1449/PTO | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 4 | | Application Number | 10/580,477 | |
| | | Filing Date | May 24, 2006 | |
| | | First named Inventor | David L. EPSTEIN | |
| | | Group Art Unit | Not yet assigned | |
| | | Examiner name | Not yet assigned | |
| | | Attorney Docket Number | 017425-9004-01 | |
| U.S. Patent Documents | | | | |
| Examiner Initials | | U.S. Patent Document Number | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document |
| /ZF/ | | 5,753,230 | Brooks et al. | 05/19/1998 |
| /ZF/ | | 5,811,515 | Grubbs et al. | 09/22/1998 |
| /ZF/ | | 5,856,336 | Fujikawa et al. | 01/05/1999 |
| /ZF/ | | 5,900,414 | Sugrue et al. | 05/04/1999 |
| /ZF/ | | 2003/0207925 | Cameron et al. | 11/06/2003 |
| /ZF/ | | 2005/0239871 | Hellberg et al. | 10/27/2005 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------|--------------------------------|---|---------------------------------------|-------------|------------------|
| Examiner Initials | Country Code | Foreign Patent Document Number | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document | Translation | English Abstract |
| /ZF/ | EP | 363,934 | Sandoz AG | 04/18/1990 | | |
| /ZF/ | EP | 491,226 | Bayer AG | 06/24/1992 | | X |
| /ZF/ | EP | 738,510 | Oreal | 10/23/1996 | | X |
| /ZF/ | JP | 10-17488 | Asahi Glass Co., Ltd. | 01/20/1998 | X | |
| /ZF/ | WO | 97/06791 | The Scripps Research Institute | 02/27/1997 | | |
| /ZF/ | WO | 2005/105155 | Saitama Medical School | 11/10/2005 | | |

| | | | |
|--------------------|---------------------------|-----------------|--|
| Examiner Signature | /Zohreh Fay/ (08/01/2010) | Date Considered | |
|--------------------|---------------------------|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|--|--------------------------|------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 3 of 4 | | Application Number | 10/580,477 |
| | | Filing Date | May 24, 2006 |
| | | First named Inventor | David L. EPSTEIN |
| | | Group Art Unit | Not yet assigned |
| | | Examiner name | Not yet assigned |
| | | Attorney Docket Number | 017425-9004-01 |
| U.S. Patent Documents | | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | |
|---|---|
| Examiner Initials | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /ZF/ | Collaborative Normal-Tension Glaucoma Study Group. "Comparison of Glaucomatous Progression Between Untreated Patients with Normal-Tension Glaucoma and Patients with Therapeutically Reduced Intraocular Pressures," <i>American Journal of Ophthalmology</i> , vol. 126, no. 4, October 1998, pages 487-97, Elsevier Science Inc., 1998. |
| | Avila, Marcel, et al., "The Effects of RGD (Arg-Gly-Asp) Peptides on Glaucoma Filtration Surgery in Rabbits," <i>Ophthalmic Surgery and Lasers</i> , April 1998, vol. 29, no. 4, pages 309-17. |
| | Comparato, C., et al., "Clinically relevant pleiotropic effects of statins: Drug properties or effects of profound cholesterol reduction?" <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , vol. 11, no. 5, October 2001, pages 328-43, Medikal Press s.r.l., Milan, Italy. |
| | Edwards, Peter A., and Johan Ericsson, "Sterols and Isoprenoids: Signaling Molecules Derived from the Cholesterol Biosynthetic Pathway," <i>Annual Review of Biochemistry</i> , vol. 68, 1999, pages 157-85, Annual Reviews, Palo Alto, California. |
| | Hall, Nigel F., et al., "Risk of macular degeneration in users of statins: cross sectional study," <i>BMJ</i> , 2001, 323 (7309), pages 375-76, http://bmj.bmjournals.com/cgi/content/full/323/7309/375 . |
| | Hershkovitz, Rami, et al., "Nonpeptidic Analogues of the Arg-Gly-Asp (RGD) Sequence Specifically Inhibit the Adhesion of Human Tenon's Capsule Fibroblasts to Fibronectin," <i>Investigative Ophthalmology & Visual Science</i> , April 1994, vol. 35, no. 5, pages 2585-91, Association for Research in Vision and Ophthalmology. |
| | Kagansky, N., et al., "Cholesterol lowering in the older population: time for reassessment?," <i>QJM</i> , vol. 94, no. 9, September 2001, pages 457-63, Oxford University Press, Association of Physicians, 2001. |
| | Kass, Michael A., "The Ocular Hypertension Treatment Study," <i>Archives of Ophthalmology</i> , vol. 120, June 2002, pages 701-13, American Medical Association. |
| | Laties, Alan M., et al., "Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results II. Assessment of the Human Lens After 48 Weeks of Treatment with Lovastatin," <i>The American Journal of Cardiology</i> , March 1, 1991, vol. 67, no. 6, pages 447-53. |
| | Lowenstein, John M., ed., <i>Methods in Enzymology</i> , "Lipids," Part C, vol. 71, pages 455-509, Academic Press, Inc., New York, 1981. |
| | McCarty, Catherine A., et al., "Cholesterol-lowering medications reduce the risk of age-related maculopathy progression," <i>The Medical Journal of Australia</i> , vol. 175, no. 6, 17 September 2001, page 340, Australian Medical Association. |

| | | | |
|--------------------|---------------------------|-----------------|--|
| Examiner Signature | /Zohreh Fay/ (08/01/2010) | Date Considered | |
|--------------------|---------------------------|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|--|---|------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 4 of 4 | | Application Number | 10/580,477 |
| | | Filing Date | May 24, 2006 |
| | | First named Inventor | David L. EPSTEIN |
| | | Group Art Unit | Not yet assigned |
| | | Examiner name | Not yet assigned |
| | | Attorney Docket Number | 017425-9004-01 |
| U.S. Patent Documents | | | |
| /ZF/ | | McGwin, Gerald, Jr., et al., "Statins and Other Cholesterol-Lowering Medications and the Presence of Glaucoma," <i>Arch Ophthalmol</i> , vol. 122, June 2004, pages 822-26. | |
| | | McGwin, Gerald, Jr., et al., "The association between statin use and age related maculopathy," <i>British Journal of Ophthalmology</i> , 2003; 87, pages 1121-25, from www.bjophthalmol.com , 6 July 2006. | |
| | | Pardridge, William M., <i>Peptide Drug Delivery to the Brain</i> , page 247, Raven Press, New York, 1991. | |
| | | Rao, P. Vasantha, et al., "Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y-27632," <i>Investigative Ophthalmology & Visual Science</i> , vol. 42, no. 5, April 2001, pages 1029-37, Association for Research in Vision and Ophthalmology. | |
| | | Ruoslahti, Erkki, and Michael D. Pierschbacher, "Arg-Gly-Asp: A Versatile Cell Recognition Signal," <i>Cell</i> , Vol. 44, 517-18, February 28, 1986, Cell Press, 1986. | |
| | | Schlienger, Raymond G., et al., "Risk of Cataract in Patients Treated with Statins," <i>Archives of Internal Medicine</i> , vol. 161, September 10, 2001, pages 2021-26, American Medical Association, Chicago, IL. | |
| | | Shovman, Ora, et al., "Antiinflammatory and Immunomodulatory Properties of Statins," <i>Immunologic Research</i> , 25/3, pages 271-85, Humana Press Inc., 2002. | |
| | | Song, Julia, et al., "Effects of Cholesterol-Lowering Statins on the Aqueous Humor Outflow Pathway," <i>Investigative Ophthalmology & Visual Science</i> , July 2005, vol. 46, no. 7, pages 2424-32, Association for Research in Vision and Ophthalmology. | |
| | | Song, Julia, et al., "Effects of cholesterol lowering statin drugs on the aqueous humor outflow pathways," webpage: http://www.abstractsonline.com/viewer/viewAbstractPrintFriendly.asp?CKey=156F3C070-... 4/6/2004, Oasis, Online Abstract Submission and Invitation System - Program Planner, one page abstract. | |
| | | Takemoto, Masao, and James K. Liao, "Pleiotropic Effects of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors," <i>Journal of the American Heart Association</i> , vol. 21, no. 11, November 2001, pages 1712-19, American Heart Association, Inc., 2001. | |
| | | Yalpani, Manssur, "Cholesterol-lowering drugs," <i>Chemistry & Industry</i> , no. 3, 5 February 1996, pages 85-89, Society of Chemical Industry, East Sussex, UK. | |

T:\cliental\017425\9004\A159425.1

| | | | |
|-----------------------|---------------------------|--------------------|--|
| Examiner Signature | /Zohreh Fay/ (08/01/2010) | Date Considered | |
|-----------------------|---------------------------|--------------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 2031.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.